Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 141 CLL / VIsion trial of ibrutinib + venetoclax in relapsed or refractory CLL
NL-OMON60649Phase 2Completed
- Sponsor
- HOVON
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival status 12 months after stopping therapy. Started Jul 2017; status: completed.
02
Drugs
ibrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON60649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60649.